secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056886
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology Q1 net loss widens to $35.6M; evorpacept B-NHL data shows 83% CRR
------------------------------------------------------------------------------

- GAAP net loss $35.6M ($0.71/sh) vs $30.2M ($0.74/sh) in Q1 2023; non-GAAP loss $28.5M vs $23.8M.
- Cash & investments $184.5M as of Mar 31; subsequent ATM raised ~$26.2M net; runway into Q1 2026.
- Evorpacept + R2 in R/R B-NHL IST: ORR 94%, CRR 83% (historical R2 CRR 34%) in 20 patients.
- Upcoming milestones: ASPEN-07 data at ASCO June 2; ASPEN-06 top line July 2024; Phase 3 init Q4 2024.
- Appointed Allison Dillon, Ph.D., as Chief Business Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/0000950170-24-056886-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000095017024056886/alxo-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056886

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer